Trial Profile

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: a Phase ll Randomised Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
Indications Adenocarcinoma; Early breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Neo-CheckRay

Most Recent Events

20 Dec 2024 Planned primary completion date changed from 30 Sep 2024 to 30 May 2025.
13 Mar 2024 Planned End Date changed from 15 Jan 2026 to 30 Sep 2029.
13 Mar 2024 Planned primary completion date changed from 31 Jan 2024 to 30 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com